FDA Informed Consent Guidance Under Development; HIV Studies Present Unique Challenges
When early “cure” research is unlikely to lead to study participants’ own HIV cure, the informed consent hurdle is high, patients told FDA. But will new guidance offer sufficient help and a successful path forward?
You may also be interested in...
US agency's April 6 patient-focused drug development meeting on sarcopenia sent two very divergent messages about the status of measuring patient engagement on new drug development: both delivered by an unexpected messenger, former FDAer Ray Lipicky.
Siga CSO Dennis Hruby talked with the Pink Sheet about the company’s plans for development of Tpoxx for monkeypox in the US. If the necessary emergency declaration is made that would let FDA issue EUAs, the company would likely try to apply with its current clinical trial-less data set.
Biden administration will run out of supply of Lilly’s covid antibody bebtelovimab in August, forcing a shift to commercial market due to lack of funds. The transition will require changes to the emergency use authorization and involve a price hike.